Holen Sie sich die Stockscreener-App
14.18
30.21%
3.29
Schlusskurs vom Vortag:
$10.89
Offen:
$14.18
24-Stunden-Volumen:
187.20M
Relative Volume:
23.21
Marktkapitalisierung:
$4.38B
Einnahmen:
$571.16M
Nettoeinkommen (Verlust:
$-38.10M
KGV:
-115.76
EPS:
-0.1225
Netto-Cashflow:
$-48.91M
1W Leistung:
+34.41%
1M Leistung:
+45.73%
6M Leistung:
+147.47%
1J Leistung:
+45.73%
1-Tages-Spanne:
$14.16
$14.36
1-Wochen-Bereich:
$10.50
$14.36
52-Wochen-Spanne:
$5.51
$14.36
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Firmenname
Amicus Therapeutics Inc
Sektor
Branche
Telefon
(609) 662-2000
Adresse
47 HULFISH STREET, PRINCETON, NJ
Vergleichen Sie FOLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.18 | 3.36B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.20 | 113.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
767.96 | 78.69B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.23 | 52.32B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.99 | 52.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.84 | 35.52B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Eingeleitet | Citigroup | Buy |
| 2025-09-18 | Hochstufung | Needham | Hold → Buy |
| 2025-07-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Eingeleitet | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2024-05-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Fortgesetzt | Goldman | Neutral |
| 2022-01-14 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-27 | Eingeleitet | Needham | Hold |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2021-02-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-02-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-05 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Eingeleitet | Janney | Buy |
| 2019-01-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Eingeleitet | Citigroup | Neutral |
| 2018-08-17 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
| 2017-09-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-08-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-01-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Eingeleitet | BofA/Merrill | Buy |
| 2016-04-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2016-04-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2015-09-16 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
Top Biotech Stocks To Add to Your WatchlistDecember 20th - MarketBeat
Amicus Therapeutics Stock Surges Post-BioMarin Acquisition Announcement - StocksToTrade
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
BioMarin to acquire Amicus Therapeutics for $4.8 billion - MSN
Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion - ts2.tech
After shakeup under new CEO, drugmaker BioMarin turns its cash on a big deal - The Business Journals
BioMarin to acquire rare disease drug developer Amicus for $4.8B - MSN
Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger - Finviz
Amicus Therapeutics Sees Stock Surge Amid BioMarin Acquisition Deal - timothysykes.com
Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025) - ts2.tech
Assenagon Asset Management S.A. Lowers Stake in Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin to buy Amicus Therapeutics for $4.8 billion - MSN
BioMarin to acquire Amicus Therapeutics for $4.8 billion By Investing.com - Investing.com South Africa
Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open - ts2.tech
Amicus Therapeutics Inc. (FOLD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
San Rafael’s BioMarin Drops $4.8 Billion Bet On Rare-Disease Rival - Hoodline
Health Care Up Amid Deal Activity -- Health Care Roundup - MarketWatch
BioMarin, Amicus Agree To $4.8bn Buyout, Combining Rare Disease Portfolios - Citeline News & Insights
Officer Clark Files To Sell 25,642 Of Amicus Therapeutics Inc [FOLD] - TradingView — Track All Markets
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today - Yahoo Finance
Rare earth: Biomarin to use global reach post-$4.8B Amicus buy - BioWorld MedTech
BioMarin Stock Jumps After Nearly $5 Billion Amicus Therapeutics Deal - Barron's
BioMarin to expand portfolio with $4.8B buy of Amicus - The Pharma Letter
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare disease company with a presence in Philadelphia - MSN
BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition - MedCity News
Amicus Therapeutics: A Surge Worth Noticing? - StocksToTrade
Promising Biotech Stocks To Follow NowDecember 19th - MarketBeat
BioMarin to acquire Amicus Therapeutics for $4.8B - Axios
BioMarin soars 20% after folding in the $4.8 billion takeover of Amicus - MSN
Amicus Therapeutics (FOLD) Surges Over 30% Amid Positive Market Activity - GuruFocus
BioMarin Reaches $4.8 Billion Definitive Agreement to Acquire Amicus Therapeutics - PharmExec.com
BioMarin is buying Amicus Therapeutics for $4.8 billion - Inquirer.com
Carnival Posts Strong Q4 Earnings, Joins Amicus Therapeutics, Biomarin Pharmaceutical And Other Big Stocks Moving Higher On Friday - Benzinga
BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion - The Wall Street Journal
BioMarin Inks $4.8B Amicus Buy As Patent Litigation Resolved - Law360
Amicus Therapeutics (NASDAQ:FOLD) Shares Gap UpTime to Buy? - MarketBeat
Amicus Therapeutics (FOLD) Downgraded by Needham to 'Hold' | FOL - GuruFocus
BioMarin makes its largest-ever transaction, paying $4.8B for fellow rare disease drugmaker Amicus - Fierce Pharma
Needham & Company LLC Reaffirms "Hold" Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Kirkland Advises Amicus Therapeutics on $4.8 Billion Sale to BioMarin - Kirkland & Ellis LLP
Amicus Therapeutics (FOLD) Downgraded by Cantor Fitzgerald | FOL - GuruFocus
Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders - PR Newswire
BioMarin to buy Amicus Therapeutics for $4.8 billion in rare disease bet - MSN
BioMarin Pharmaceutical Inc. agreed to acquire Amicus Therapeutics, Inc. for $4.7 billion. - marketscreener.com
Amicus Therapeutics (NASDAQ:FOLD) Receives Neutral Rating from Cantor Fitzgerald - MarketBeat
Amicus Therapeutics (FOLD) Shares Surge Over 30% - GuruFocus
BioMarin Pharmaceutical to Acquire Amicus Therapeutics in $4.8 Billion Deal - marketscreener.com
BioMarin buys pharma peer Amicus for $4.8bn - Sharecast.com
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion in All‑Cash Deal, Expanding Rare Disease Drug Portfolio - ts2.tech
BioMarin Pharmaceutical to Acquire Amicus Therapeutics for $4.8 Billion; Shares Jump - marketscreener.com
Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):